%0 Journal Article
%T First-generation versus second-generation long-acting injectable antipsychotic drugs and time to relapse
%A David Taylor
%A James M. Stone
%A Paul D. Morrison
%A Simon Roux
%J Archive of "Therapeutic Advances in Psychopharmacology".
%D 2018
%R 10.1177/2045125318795130
%X The development of long-acting injectable formulations (LAIs) of second-generation antipsychotic drugs (SGAs) has been suggested as having advantage over first-generation antipsychotic (FGA) LAIs. In this study, we investigated the hypothesis that there was a longer time to relapse in patients with schizophrenia started on SGA LAI versus FGA LAI
%K Depot
%K antipsychotic
%K schizophrenia
%K efficacy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278743/